Current medical news and unique business news for anyone who cares about the healthcare industry.
The superbug strikes back. Europe is losing the war on superbugs while super superbugs are now in the water supply in India. IBM and nanotech researchers, however, think they’ve found a way to leverage nanotechnology to attack some forms of antibiotic-resistant bacteria, including MRSA.
Rivlin: I don’t support Ryan’s reform. Congressman Paul Ryan has said he and former Clinton appointee Alice Rivlin designed his proposed healthcare reform legislation around Medicaid and Medicare reform. Well, it turns out Rivlin does not support Ryan’s proposal. Whoops!
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Off-label marketing. A new study of dozens of whistleblower lawsuits chronicles all the dirty tricks of the trade in marketing off-label drug uses. But the only way to curb illegal marketing of drugs is for physicians to become better educated on the topic, according to the report.
Venture capital elitism… is actually becoming a bad thing.
Already, with far fewer venture firms in charge, things have grown strange. Who would have imagined Kleiner Perkins would be hunting down deals on the secondary market, or that a mobile photography app would garner $41 million before attracting its first user, or that investors’ obsession with daily group buying sites would grow quite so intense? (If you didn’t pay much attention to the news of LivingSocial’s fresh, $400 million investment this week, it may be because it marked the eighth $100-million-plus deal so far this year.)
Autism… is becoming a luxury of the rich.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Vandetanib FDA approval. The U.S. Food & Drug Administration has approved AstraZeneca’s thyroid cancer drug. As many as 2,200 cancer patients have the type of thyroid cancer treated by the drug.
